UNSPSC 51293007: Noxiptiline

This classification denotes an antidepressant agent with the molecular formula C19H22N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DF7D3NY7EL, chemically known as 10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-on-o-(2-(dimethylamino)ethyl)oxim but generally known as noxiptiline, which bears US NIH Compound Identifier 21087. European Medicines Agency schedules Noxiptiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09386MIG.

UNSPSC 51293007 Noxiptiline is a Commodity code for pharmaceutical products, but the recent opportunities tagged under it reflect a much broader pharmaceutical procurement activity — state and local governments are actually buying naloxone (opioid antagonist), safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing arrangements. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work ranges from small, direct acquisitions of specific pharmaceutical products for community health programs to large-scale cooperative contracts supplying generic pharmaceuticals and OTC products across multiple jurisdictions through authorized wholesalers.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida posted an IFB on June 30, 2026 (response due July 26, 2023) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building; the contract includes a two-year initial term with one-year renewal option and carries a three-month probationary period. The Texas HHS Commission issued an RFI on April 3, 2026 regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to gather vendor capabilities for establishing direct relationships between the state's pharmacy benefit program and manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP, administered by the Minnesota Department of Administration, released an RFP on January 20, 2026 (response due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities, requiring vendors to supply through three authorized wholesalers with products available by May 15, 2026 and contracts effective July 1, 2026; evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing for contract term, and 5 percent each on administrative fee format compliance, EDI capability, and agreement to a 3 percent administrative fee.